Accord Healthcare, Inc. is voluntarily recalling a single lot of Daptomycin for Injection 500 mg/vial, and Daptomycin for Injection 350 mg/vial product contained in cartons imprinted with lot # R2200232 Exp: 01/2025 to the consumer/user level.

This product is being recalled because Accord received a product complaint report from a hospital pharmacy that vials labeled as “Daptomycin for Injection 500 mg/vial” were found in cartons labeled as “Daptomycin for Injection 350 mg/vial”.

Click for more on Drug recall

The lot and expiration date printed on the outer carton and inner vial are the same and correspond to “Daptomycin for Injection 500 mg/vial.”

Accordingly, Accord is voluntarily recalling all of lot #R2200232, Daptomycin for Injection 500 mg/vial, which may be in outer cartons that read “Daptomycin for Injection 500 mg/vial” OR “Daptomycin for Injection 350 mg/vial.” 

ProductNDCLot number/Expiration DateDaptomycin for Injection 500 mg/vial16729-435-05R2200232, 01/2025Daptomycin for Injection 350 mg/vial16729-434-05

Click for more on Daptomycin for injection

Risk Statement: Administration of Daptomycin 500 mg/vial, to the population most at risk which are children or patients with renal impairment, there is a reasonable probability that the likelihood of the labeled warnings can potentially be increased if a higher than the intended dose is used which could lead to serious adverse health consequences.

If these reactions occur, they may require medical treatment such as hemodialysis and systemic glucocorticoids. To date, Accord has not received any reports of adverse events related to this recall.

The product is used for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria:

- Staphylococcus aureaus (including methicillin-resistant isolates),

- Streptococcus pyogenes,

- Streptococcus agalactiae,

- Streptococcus dysgalactiae subsp. equisimilis,

- Enterococcus faecalis (vancomycin-susceptible isolates only).

The lot number, NDC number and expiration date of affected Daptomycin 500 mg/vial and Daptomycin 350 mg/vial product is shown in the table below:

ProductNDCLot number/Expiration DateDaptomycin for Injection 500 mg/vial16729-435-05R2200232, 01/2025Daptomycin for Injection 350 mg/vial16729-434-05

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (USFDA).

Other drugs recall

Drug recall: Vancomycin Hydrochloride Injection recalled due to this reason

Drug recall: 4 lots of Quinapril Tablets recalled due to this reason

Drug recall: This Blood Pressure tablets recalled

Drug recall: Sodium Bicarbonate Injection recalled due to this reason

Drug recall: Dr Reddy’s, Sun Pharma recall these drugs due to this reason

Drug recall: FDA issues nationwide recall for Ferric Carboxymaltose

New BCG vaccine for TB: Clinical trials to start soon

Drug licences of these two firms suspended: FDA Manipur

Fake pharma firm busted, two arrested

USFDA approves Fesoterodine Fumarate Extended-Release tablets

Medical Device alert: CDSCO issues medical device alert on MitraClip Clip Delivery System

Drug recall: Vancomycin Hydrochloride Injection recalled due to this reason

List of approved New Drugs Updated

No need to recall, re-label the drug for price revision if…….:NPPA

Registration for sale of Medical Devices: Procedure and conditions

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2023/01/07/drug-recall-daptomycin-for-injection-recalled-due-to-this-reason/